Cetraxal

Ciprofloxacin

Method of action: Antibacterial Broad Spectrum (Bactericidal), Bactericidal

Treatment option: Blepharitis, Blepharoconjunctivitis, Gonorrhea, Keratitis, Keratoconjunctivitis, Otitis Externa, Acute Otitis Externa, Ophthalmic Surgery, Peritonitis, Prostatitis

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cetraxal

Property	Description
Active ingredient	Ciprofloxacin
Form	Sterile Otic Solution (Ear Drops)
Pharmacological class	Fluoroquinolone Antibiotic
Common use	To eliminate bacterial ear infections
Origin	Synthetic Antimicrobial Agent

Cetraxal is a specialized prescription-only medicine whose active ingredient is Ciprofloxacin, a synthetic antimicrobial agent used for localized infections within the ear canal. This product is formulated exclusively as a single-ingredient otic solution, which emphasizes its intended use for direct, topical application. Its fundamental purpose is to introduce a potent antibacterial agent precisely to the site of infection to resolve the bacterial cause of the condition.

What Type of Medicine Is Cetraxal?

Ciprofloxacin belongs to the fluoroquinolone class of antibiotics, distinguished by their rapid, bactericidal mechanism of action. This classification identifies the drug as a synthetic agent with a targeted mechanism against bacterial pathogens. Ciprofloxacin works by interfering with two critical bacterial enzymes, DNA gyrase and topoisomerase IV, necessary for DNA synthesis and bacterial survival. The use of Ciprofloxacin in the treatment of ear infections is based on its high activity against common causative pathogens.

Formulation and Specialized Administration Route

The Cetraxal brand is supplied as a sterile, preservative-free otic solution (ear drops), defining its specialized physical form and delivery system. A key feature is its formulation as a single-ingredient product, contrasting with other otic preparations that may combine the antibiotic with a corticosteroid. The solution contains Ciprofloxacin monohydrochloride monohydrate, the active salt form, delivered in an aqueous-based vehicle, and is often packaged in convenient, single-dose containers. This specialized route of administration is strictly for auricular (otic) use only, focusing the antimicrobial effect directly into the ear canal, which allows for targeted treatment of localized infections.

Regulatory References

What side effects are possible with Cetraxal ?

Possible Side Effects and Safety Information

The official safety information for Ciprofloxacin Otic Solution (Cetraxal) documents adverse reactions primarily related to the application site, classified by frequency and grouped by the organ systems affected. This section adheres strictly to the regulatory descriptions found in authoritative government sources like the EMA Summary of Product Characteristics (SmPC) and the FDA Prescribing Information.

Frequency-Classified Adverse Reactions

The most commonly documented reactions in clinical studies include Ear and Labyrinth Disorders, such as ear pruritus (itching) and otic pain, which are classified as Common (1/100 to < 1/10 incidence). Adverse reactions classified as Uncommon (1/1000 to < 1/100) include Paraesthesia (tingling), Hypoesthesia (numbness), and local Dermatitis.

System-Organ Class Involvement

Adverse effects are formally categorized into System-Organ Classes (SOC). The primary SOCs involved are Ear and Labyrinth Disorders, Skin and Subcutaneous Tissue Disorders, and Nervous System Disorders (e.g., Headache, Dizziness).

Serious Adverse Reactions and Class Warnings

The safety profile includes warnings for rare but serious adverse events associated with the entire fluoroquinolone class. These include potential systemic reactions such as severe hypersensitivity events like Angioedema, Stevens-Johnson syndrome (SJS), and Toxic Epidermal Necrolysis (TEN). Additionally, rare systemic effects like tendon rupture and tendinitis are noted as class warnings.

Safety Constraints and Considerations

The medicine is formally contraindicated in individuals with a history of hypersensitivity to ciprofloxacin or to any other member of the quinolone class of antimicrobial agents. The label also specifies that prolonged use of the solution may result in the overgrowth of non-susceptible organisms, including fungi (superinfection). Safety information for pediatric patients is established, but use is not documented for infants younger than one year of age in some regulatory labels.

Overdose and Emergency Response

Overdose Scope

Documented overdose presentations: The systemic exposure from otic administration of Ciprofloxacin is minimal, meaning a severe systemic overdose is not anticipated from prescribed use. The documented manifestation of concern is primarily related to accidental oral ingestion of the solution.

Physiological systems affected (as stated in label): Regulatory guidance addresses the potential for central nervous system (CNS) and respiratory compromise that would lead to collapse or trouble breathing, which are the stated triggers for immediate emergency service contact.

Dose-related or exposure-related factors (if applicable): The overdose scenario is associated with the route of exposure being oral ingestion rather than the prescribed topical route.

Population-specific overdose notes (if applicable): No specific, increased overdose risks or distinct manifestations for pediatric, geriatric, or renally impaired patients are explicitly detailed in the otic overdose sections of the regulatory labels reviewed.

Emergency-response statements (as written in official documents):

Contact a Poison Control Center immediately for accidental oral ingestion.
Call emergency services (e.g., 911 or local equivalent) if the individual collapses or is not breathing.

When immediate medical help is required (label-derived phrasing only): When the medicine has been accidentally swallowed (requires Poison Control/medical attention) or when collapse or respiratory distress occurs (requires emergency services).

Overdose Classifications (High-Level)

Severity classification (as defined in official documents): The event is classified as potentially dangerous primarily when it involves accidental ingestion or presents with life-threatening collapse or respiratory failure signs.

Regulatory basis (EMA / FDA / etc.): The documented profile is based on U.S. Food and Drug Administration (FDA) and equivalent international regulatory guidance for Ciprofloxacin Otic Solution.

Overdose-context constraints (as defined in official documents): Overdose descriptions are constrained by the low systemic absorption characteristic of the otic formulation.

Resulting Overdose Structure

Official overdose statements:

Overdose of Ciprofloxacin Otic Solution is not expected to be dangerous when used correctly, but accidental swallowing requires immediate attention.
If the otic solution is accidentally swallowed, contact a Poison Control Center or seek professional medical advice immediately.
Immediate emergency services must be contacted if the person has collapsed or is experiencing trouble breathing following a potential overdose event.
Management is symptomatic and supportive, and no specific antidote is known to exist for this overdose.

Connection to the overall overdose profile (2–4 sentences): The regulatory documents define the overdose profile by focusing on the low probability of systemic toxicity from topical use, instead prioritizing the actions mandated for accidental oral ingestion. Official labeling requires urgent medical consultation following ingestion and mandates calling emergency services immediately if the patient exhibits critical signs like collapse or cessation of breathing.

Therapeutic Uses of Cetraxal

What Cetraxal Treats: Main Uses and Benefits

Cetraxal is a topical antibiotic solution used to provide focused treatment for localized bacterial infections in the ear. Its purpose is to help manage the infection and provide supportive relief from the intense, acute symptoms it causes, thereby supporting patient comfort. The medicine is used for the treatment of specific outer ear infections.

Key Therapeutic Focus

This medication is considered relevant for managing Acute Otitis Externa (AOE), commonly known as Swimmer's Ear, which is a condition involving the external ear canal often associated with water exposure, and managing persistent ear discharge (otorrhea) when it is caused by a bacterial infection draining through surgically placed tympanostomy tubes (ear tubes). Cetraxal is applied in conditions marked by heightened symptoms, including significant ear pain (otalgia), visible inflammation, and swelling.

“This focused application is considered relevant in supporting the reduction of the bacterial load and helps ease the overall symptom burden of these distressing manifestations.”

The medicine provides supportive relief from the severe, acute symptoms associated with these ear infections. By addressing the causative bacteria, Cetraxal may assist with the reduction of pain and the easing of discharge and canal swelling, which, in turn, may help contribute to improved day-to-day comfort. This usage may be applied in providing temporary assistance in symptom stabilization for adults and pediatric patients (typically children one year of age and older).

Quick Fact: Relief for Acute Pain and Discharge Cetraxal is commonly used to help with symptoms related to inflammatory or irritative states and provides supportive relief when symptoms interfere with routine activities.

Eligibility and Restrictions for Use

Who Can and Cannot Use Cetraxal?

The eligibility for using Cetraxal (Ciprofloxacin otic solution) is defined by official regulatory documentation, focusing on age restrictions and specific drug hypersensitivities.

Approved and Restricted Populations

Cetraxal is approved for use in adult patients and pediatric patients aged one year and older for the labeled treatment of ear infections. Its safety and effectiveness have not been established in infants below one year of age, which places this group under a restricted or conditional use classification. No overall differences in safety have been observed in older adults, meaning age alone is not typically a barrier to use in that group.

Because the medicine is an ear drop with negligible systemic absorption, regulatory bodies state that no dose adjustment is necessary for patients with existing renal or hepatic impairment; therefore, these conditions do not restrict eligibility.

Absolute Non-Eligibility (Contraindications)

Cetraxal is formally contraindicated (must not be used) in individuals with a known history of hypersensitivity or allergic reaction to its active ingredient, ciprofloxacin, or to any other antibiotic belonging to the quinolone class of medications.

Pregnancy and Lactation Status

Due to the minimal systemic exposure from otic administration, minimal risk is expected during pregnancy, though caution is still advised. For nursing mothers, a decision must be made to discontinue nursing or discontinue the drug, taking into account the drug's importance to the mother.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Cetraxal (Ciprofloxacin Otic Solution) is strictly determined by its localized route of administration. Ciprofloxacin, when applied topically as an ear drop solution, results in negligible systemic exposure in the bloodstream, a key factor noted in regulatory documentation.

Specific drug interaction studies have not been conducted for the otic solution. Due to the minimal systemic absorption, the clinically significant drug-drug, drug-food, and metabolic interactions that are well-documented for the oral or intravenous forms of ciprofloxacin are not expected to be relevant to this topical product.

Official Interaction Restrictions

Restriction Category	Status in Regulatory Documents
Contraindicated Drug Combinations	None documented based on interaction risk.
Systemic Exposure-Altering Interactions	None documented; systemic exposure is negligible.
Timing or Separation Requirements	None documented for co-administered medicines.
Interactions with Food or Supplements	None documented.

Regulatory agencies classify the potential for clinically significant systemic drug-drug interaction with Cetraxal as minimal to absent. The official labeling therefore lists no specific interacting medicinal products or mandatory restrictions on co-administration with other systemic medicines or substances based on interaction concerns.

Mechanism of Action

Pharmacodynamics: Mechanism of Action

The Cetraxal molecule, Ciprofloxacin, functions as a DNA scission poison targeting essential bacterial enzymes. Its primary biological targets are DNA Gyrase (Topoisomerase II) and Topoisomerase IV within susceptible bacterial cells. Ciprofloxacin interacts with the enzyme-DNA complex, binding specifically to and stabilizing the intermediate state where the DNA strand has been cut but not yet rejoined. This type of molecular interaction classifies Ciprofloxacin as an enzyme inhibitor and a topoisomerase poison.

This stabilization blocks the enzymes from completing the strand-rejoining process, effectively trapping them as physical roadblocks on the bacterial genome. The resulting mechanistic cascade leads to the accumulation of catastrophic double-strand DNA breaks whenever the cell attempts DNA replication or transcription. This overwhelming, irreparable genetic damage triggers the rapid structural collapse and death of the susceptible bacterial cell, resulting in a system-level bactericidal effect that removes the pathogen population.

Dosage and Administration Information

Administration and Dosage

Cetraxal is an otic solution administered topically into the ear canal and is not for injection, inhalation, or ophthalmic use. The contents of one single-use container (0.25 mL deliverable volume) must be instilled into the affected ear twice daily (approximately 12 hours apart) for a total treatment duration of seven days. This dosage applies to adults and children one year of age and older.

Official Procedural Steps

The following procedural steps are mandated for the correct administration of the ear drops:

Wash hands thoroughly before handling the medication.
Warm the container by holding it in your hands for at least one minute prior to use to minimize potential dizziness from cold solution instillation.
Lie down or tilt your head with the affected ear facing upward.
Instill the entire contents of the single-use container into the ear canal.
Maintain the position with the affected ear upward for at least one minute to facilitate the drops' penetration.
Discard the container immediately after use, even if any solution remains, as each container is for single use only.
If a dose is missed, it should be administered as soon as remembered. However, if it is almost time for the next scheduled dose (e.g., within 6-8 hours), the missed dose should be skipped, and the regular schedule resumed. Do not double the dose to compensate.

Recent Clinical Evidence

Research evidence / Overview of studies for Cetraxal

Evidence for Use in Acute Otitis Externa (AOE)

Research exploring the use of Ciprofloxacin otic solution for Acute Otitis Externa (AOE), commonly known as Swimmer's Ear, primarily involves randomized controlled trials (RCTs). These short-term studies were structured to compare the solution against other established topical antibiotic treatments. Researchers examined outcomes related to physical discomfort, such as the status of pain and swelling, as well as the status of ear discharge. Trials also monitored the clearance of the specific bacteria that commonly cause AOE.

The studies monitored how symptoms evolved over the defined time intervals. In research designed to show that the Ciprofloxacin solution was not worse than existing treatments (non-inferiority trials), the findings described outcomes that were comparable to those observed in the groups using the comparator topical treatments. This evidence contributes to the broader evidence landscape for single-agent topical antibiotics.

Evidence for Use in Ear Discharge with Tympanostomy Tubes

Clinical trials have also studied Ciprofloxacin otic solution for managing ear discharge (otorrhea) in pediatric patients who have surgically placed tympanostomy tubes (ear tubes). This research involved RCTs that compared the topical solution to systemic (oral) antibiotics and to non-antibiotic treatments.

In these comparative research scenarios, the studies reported how symptoms evolved in the observed populations. Trials described patterns where the groups observed using the topical Ciprofloxacin solution had a shorter measured time to cessation of discharge compared to groups using oral antibiotics. Similarly, the documented rates of persistent discharge were different between the topical treatment groups and comparator groups. The evidence contributes to understanding symptom patterns in this specific patient population.

What Remains Uncertain in the Evidence Base

Data for certain groups remain insufficient. For example, regulatory reviews indicate that research on AOE may be more extensive relative to the adult population in some initial regulatory studies. Furthermore, the evidence base is characterized by follow-up durations that were limited, typically observing responses over defined time intervals of just a few weeks. Long-term effects are not fully established, and certainty remains low regarding outcomes beyond the short periods studied. Research is ongoing to fully understand all patterns related to this solution.

Frequently Asked Questions (FAQ)

Common questions about Cetraxal (FAQ)

Q: Is Cetraxal the same as Ciprofloxacin?

Cetraxal is the brand name used for this specific otic medicine. The active ingredient it contains is Ciprofloxacin, which is classified as a fluoroquinolone antibiotic. Ciprofloxacin is the medicinal substance that provides the antibacterial effect, while Cetraxal is the specific product containing it.

Q: Does Cetraxal contain steroids?

Official product information describes Cetraxal as a single-ingredient otic (ear) solution. It contains only the antibiotic Ciprofloxacin. This specific product is steroid-free, though some other ear drop preparations may combine an antibiotic with a corticosteroid.

Q: Can Cetraxal be used for infections in other parts of the body besides the ear?

No. Cetraxal is a specialized otic solution (ear drops) and is indicated only for treating localized bacterial infections within the ear canal. Regulatory documents specify that it is not intended for injection, inhalation, or ophthalmic (eye) use.

Q: What is the typical length of time people use Cetraxal?

According to regulatory documents, the total treatment duration for Cetraxal is a short course of seven days. The medicine is generally used for the designated duration as specified in regulatory documents.

Q: How quickly should I start feeling better after using Cetraxal?

Clinical trials often monitor outcomes such as the cessation of ear discharge or the clearance of bacteria. Official information emphasizes that the medicine is intended to be used for the full, designated treatment course.

Q: Is it normal to feel a stinging or burning sensation when putting in Cetraxal?

Local intolerance reactions at the site of application, such as ear pain or discomfort, are noted as common side effects in clinical studies. A stinging or burning sensation has been described as a possible localized reaction that can be reported.

Q: Can Cetraxal cause dizziness?

Dizziness is documented as an uncommon nervous system side effect. Additionally, administering the cold drops directly into the ear may temporarily cause dizziness, which is why the administration instructions advise warming the container beforehand.

Q: Are there any severe side effects associated with Cetraxal?

Official safety information includes warnings for serious systemic reactions associated with the fluoroquinolone drug class. These can include rare but severe hypersensitivity events such as Stevens-Johnson syndrome (SJS).

Q: Is it possible to be allergic to Cetraxal?

Yes, it is possible. Cetraxal is formally contraindicated (must not be used) in patients with a known history of hypersensitivity or allergic reaction to its active ingredient, Ciprofloxacin, or to other antibiotics in the quinolone class.

Q: Can Cetraxal interact with over-the-counter pain relievers?

Specific interaction studies for the ear drop solution have not been performed. Due to the minimal amount of medicine absorbed into the body (negligible systemic exposure), the risk for clinically significant interactions with systemic medicines, including common over-the-counter pain relievers, is considered minimal or absent.

Q: Can I use Cetraxal if I have a perforated eardrum?

Official indications for this medicine specify its use for treating ear infections in adults and children older than 1 year with an intact tympanic membrane. This means the eardrum should not have a hole or perforation.

Q: Can Cetraxal cause hearing changes?

Hearing-related changes are noted in regulatory documents. Both hypoacusis (reduced hearing) and tinnitus (a ringing or buzzing sensation in the ears) are listed as uncommon side effects.

Q: Does the evidence for Cetraxal include studies on children?

Yes. Cetraxal is approved for use in pediatric patients aged one year and older. Clinical trials that supported its approval included studies in children for treating conditions like acute otitis externa and ear discharge related to ear tubes.

Q: How long can I use Cetraxal once the bottle has been opened?

Cetraxal is supplied in single-use containers. The official guidance is that the medicine must be used immediately after opening the container, and any remaining solution must be discarded right away.

Q: Is Cetraxal available as a generic medicine?

Ciprofloxacin, the active ingredient in Cetraxal, is a widely used medicine. The active ingredient is available in generic versions for various routes of administration, including the otic solution.

Q: Can Cetraxal treat a fungal ear infection?

Cetraxal is a fluoroquinolone antibiotic designed to eliminate bacterial infections. Official warnings state that using the medicine may lead to the overgrowth of non-susceptible organisms, including fungi, which is sometimes called a superinfection.

Q: Is it possible to develop resistance to Cetraxal with repeated use?

Official warnings note that, similar to other antibiotic preparations, prolonged use or repeated courses of treatment may lead to the selection or overgrowth of non-susceptible organisms. Official warnings note that bacteria may be able to develop resistance to Ciprofloxacin with repeated use.

Q: Does Cetraxal come in different formulations (e.g., solution, suspension)?

The Cetraxal brand is formally described as a sterile otic solution (a liquid). Other brands of Ciprofloxacin ear medicine may be available as a suspension, which is a different type of liquid formulation.

Q: Are there any specific activities, like swimming, to avoid while using Cetraxal?

Patient information suggests that activities like swimming should be avoided to help ensure the infected ear remains clean and dry during treatment.

Q: What is the difference in side effects when compared to oral antibiotics?

Because the ear drop is applied topically and very little is absorbed into the bloodstream, the side effects are mainly confined to the ear and the application site. This contrasts with oral Ciprofloxacin, which results in significant systemic exposure and has different safety profile considerations.

Q: Is Cetraxal indicated for 'swimmer's ear' (otitis externa)?

Yes. Official regulatory documents state that the medicine is indicated for treating acute otitis externa (AOE). This is the medical term that refers to 'swimmer’s ear,' which is typically a bacterial infection of the outer ear canal.

Q: Why does the drug information mention tendon issues with some Ciprofloxacin products, and is this relevant to Cetraxal?

Tendon issues, such as tendon rupture, are a class warning associated with all antibiotics in the fluoroquinolone group. This is noted in Cetraxal's information because the active ingredient is Ciprofloxacin. The topical ear solution is noted to have a negligible systemic absorption, meaning the risk described for systemic products is considered low for this specific application.

Q: What information is available about potential long-term use of Cetraxal?

The medicine is intended for short-term, 7-day treatment. Regulatory documents caution that prolonged use may lead to the overgrowth of non-susceptible organisms, including fungi. Furthermore, long-term effects are not fully established beyond the limited follow-up periods of clinical studies.

Q: Is there a standard protocol for what to do if the medicine spills on the skin?

Official patient instructions advise seeking immediate medical attention if the medicine is accidentally swallowed or gets into the eyes. While no specific protocol for skin spillage is provided in the main professional labels, general guidance for topical products suggests rinsing the area with water.

Q: Is it normal for the ear to feel wet or plugged after using Cetraxal?

Yes. Side effects such as ear congestion and changes related to the tympanic membrane (eardrum) are listed as uncommon in official documents, which can contribute to a temporary wet or plugged sensation in the ear.

Q: What should I look out for if I suspect an allergic reaction to Cetraxal?

Symptoms of a serious allergic reaction may include rash, hives, or swelling of the face, throat, tongue, or lips. Patients are advised to seek medical attention if these or other serious symptoms occur, as described in the official safety information.

Q: What is the difference between Cetraxal and other ear drops?

Cetraxal is a single-ingredient antibiotic ear drop, meaning it contains only the active ingredient Ciprofloxacin. This contrasts with other otic medicines that are combination products which may include a corticosteroid (an anti-inflammatory drug) alongside an antibiotic.

How should Cetraxal be stored and disposed of?

How to Store and Dispose of Cetraxal

Cetraxal (ciprofloxacin otic solution) requires adherence to specific temperature, light, and handling rules to maintain its quality, as detailed in the official labeling.

Storage Requirements

Temperature and Protection: The single-use containers must be stored at controlled room temperature, typically 15 C to 25 C (59 F to 77 F), and must not be frozen. Unused containers should remain in the original foil overwrap pouch and carton to protect them from light.
In-Use Stability: The contents of a single-dose container must be used immediately after opening. Any unused portion in the container must be discarded immediately. The medicine must be kept out of the sight and reach of children.

Disposal Instructions

Do not throw away this medicine via household waste or wastewater. Unused medicinal product and waste material must be disposed of in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.